Cargando…
Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?
Long-term endocrine therapy with either aromatase inhibitors (AIs) or tamoxifen may lead to endocrine resistance and disease progression. Recent years have seen advances in our understanding of the complex biological mechanisms associated with resistance. Growth factor signaling pathways appear to b...
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2006
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360507/ https://www.ncbi.nlm.nih.gov/pubmed/16926831 http://dx.doi.org/10.1038/sj.bjc.6603316 |